Simon Y Graeber
Overview
Explore the profile of Simon Y Graeber including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
940
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Graeber S, Sommerburg O, Yu Y, Berges J, Hirtz S, Scheuermann H, et al.
Front Pharmacol
. 2025 Mar;
16:1537095.
PMID: 40066329
Objective: Intestinal current measurement (ICM) provides a sensitive bioassay for assessment of cystic fibrosis transmembrane conductance regulator (CFTR) function in rectal biopsies and is used as a diagnostic tool for...
2.
Jaudas F, Bartenschlager F, Shashikadze B, Santamaria G, Reichart D, Schnell A, et al.
Sci Transl Med
. 2025 Jan;
17(782):eadk9145.
PMID: 39841805
In patients with cystic fibrosis (CF), repeated cycles of infection and inflammation eventually lead to fatal lung damage. Although diminished mucus clearance can be restored by highly effective CFTR modulator...
3.
Ringwald F, Wucherpfennig L, Hagen N, Mucke J, Kaletta S, Eichinger M, et al.
Front Med (Lausanne)
. 2024 Nov;
11:1401473.
PMID: 39606627
Introduction: Segmentation of lung structures in medical imaging is crucial for the application of automated post-processing steps on lung diseases like cystic fibrosis (CF). Recently, machine learning methods, particularly neural...
4.
Wielputz M, Stahl M, Triphan S, Wucherpfennig L, Leutz-Schmidt P, Gestewitz S, et al.
Ann Am Thorac Soc
. 2024 Sep;
PMID: 39255452
Rationale: The progression of lung changes in cystic fibrosis (CF) from infancy through adolescence remains poorly understood due to limited longitudinal imaging data. Objectives: To assess changes in lung morphology...
5.
Arenhoevel J, Kuppe A, Addante A, Wei L, Boback N, Butnarasu C, et al.
Biomater Sci
. 2024 Jul;
12(17):4376-4385.
PMID: 39028033
Increased disulfide crosslinking of secreted mucins causes elevated viscoelasticity of mucus and is a key determinant of mucus dysfunction in patients with cystic fibrosis (CF) and other muco-obstructive lung diseases....
6.
Stahl M, Dohna M, Graeber S, Sommerburg O, Renz D, Pallenberg S, et al.
Eur Respir J
. 2024 Jun;
64(3).
PMID: 38901883
Background: We recently demonstrated that elexacaftor/tezacaftor/ivacaftor (ETI) improves the lung clearance index (LCI) and abnormalities in lung morphology detected by magnetic resonance imaging (MRI) in adolescent and adult patients with...
7.
Piehler L, Thalemann R, Lehmann C, Stahl M, Mall M, Graeber S
Am J Respir Crit Care Med
. 2024 Jun;
210(3):365-367.
PMID: 38843542
No abstract available.
8.
Bechtella L, Chunsheng J, Fentker K, Erturk G, Safferthal M, Polewski L, et al.
Nat Commun
. 2024 Mar;
15(1):2611.
PMID: 38521783
The dense O-glycosylation of mucins plays an important role in the defensive properties of the mucus hydrogel. Aberrant glycosylation is often correlated with inflammation and pathology such as COPD, cancer,...
9.
Pioch C, Ziegahn N, Allomba C, Busack L, Schnorr A, Tosolini A, et al.
J Cyst Fibros
. 2024 Mar;
23(5):863-869.
PMID: 38508948
Background: In health, nitric oxide (NO) shows high concentrations in the upper airways, while nasal NO (nNO) is significantly lower in patients with sinonasal inflammation, such as people with cystic...
10.
Loske J, Voller M, Lukassen S, Stahl M, Thurmann L, Seegebarth A, et al.
Am J Respir Crit Care Med
. 2024 Jan;
209(11):1338-1350.
PMID: 38259174
Pharmacological improvement of cystic fibrosis transmembrane conductance regulator (CFTR) function with elexacaftor/tezacaftor/ivacaftor (ETI) provides unprecedented improvements in lung function and other clinical outcomes in patients with cystic fibrosis (CF). However,...